The estimated Net Worth of Stefan K.F. Schwabe is at least $3.18 Milione dollars as of 21 December 2020. Stefan Schwabe owns over 46,347 units of Supernus Pharmaceuticals Inc stock worth over $1,526,619 and over the last 12 years he sold SUPN stock worth over $184,302. In addition, he makes $1,469,060 as Executive Vice President - Research and Development e Chief Medical Officer at Supernus Pharmaceuticals Inc.
Sign up
Stefan Schwabe SUPN stock SEC Form 4 insiders trading
Stefan has made over 8 trades of the Supernus Pharmaceuticals Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 46,347 units of SUPN stock worth $601,584 on 21 December 2020.
The largest trade he's ever made was exercising 95,000 units of Supernus Pharmaceuticals Inc stock on 7 September 2017 worth over $1,227,400. On average, Stefan trades about 14,721 units every 112 days since 2012. As of 21 December 2020 he still owns at least 49,119 units of Supernus Pharmaceuticals Inc stock.
You can see the complete history of Stefan Schwabe stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Stefan Schwabe biography
Dr. Stefan K. F. Schwabe M.D., Ph.D. is no longer serves as Executive Vice President - Research and Development, Chief Medical Officer of the Company effective 12/31/2020. Prior to that, Dr. Schwabe served as Chief Operating Officer at DerneRx, a privately-held biotech company, working in the area of addiction. From 2006 to 2010, Dr. Schwabe served as Vice-President for Project Direction for Neurology Projects at Sanofi-Aventis. From 2004 to 2006, he served as the Executive Director, US Clinical Development and Medical Affairs, Neuroscience for Novartis. From 1998 to 2004, Dr. Schwabe served as the Global Project Leader—Topamax for Johnson & Johnson. Dr. Schwabe served as Medical Director at Gabitril & Seroxat in the Health Care Strategy Unit, International Operations for Novo Nordisk, and both International Project Team Leader and International Clinical Team Leader—Trileptal and Scientific investigator for Ciba-Geigy. Dr. Schwabe also served as Chief Resident, Department of Neurology for the Medical College of Wisconsin in Milwaukee, Wisconsin. Dr. Schwabe received his Bachelor of Science in Chemistry from Florida International University, his M.D. from the Ludwig-Maximilians University in Munich, Germany and his Ph.D./Doctorate from the Department of Toxicology at the Technical University of Munich, Germany.
What is the salary of Stefan Schwabe?
As the Executive Vice President - Research and Development e Chief Medical Officer of Supernus Pharmaceuticals Inc, the total compensation of Stefan Schwabe at Supernus Pharmaceuticals Inc is $1,469,060. There are 2 executives at Supernus Pharmaceuticals Inc getting paid more, with Jack Khattar having the highest compensation of $8,123,130.
How old is Stefan Schwabe?
Stefan Schwabe is 68, he's been the Executive Vice President - Research and Development e Chief Medical Officer of Supernus Pharmaceuticals Inc since 2012. There are 3 older and 13 younger executives at Supernus Pharmaceuticals Inc. The oldest executive at Supernus Pharmaceuticals Inc is John Siebert, 80, who is the Independent Director.
What's Stefan Schwabe's mailing address?
Stefan's mailing address filed with the SEC is C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE, MD, 20850.
Insiders trading at Supernus Pharmaceuticals Inc
Over the last 13 years, insiders at Supernus Pharmaceuticals Inc have traded over $37,265,765 worth of Supernus Pharmaceuticals Inc stock and bought 16,600,700 units worth $83,216,588 . The most active insiders traders include Forest Baskett, Scott D Sandell e Peter J Barris. On average, Supernus Pharmaceuticals Inc executives and independent directors trade stock every 30 days with the average trade being worth of $4,263,834. The most recent stock trade was executed by Jack A. Khattar on 3 September 2024, trading 21,000 units of SUPN stock currently worth $652,680.
What does Supernus Pharmaceuticals Inc do?
pioneering new medicines in neurology and psychiatry with more than 20 years of experience, we are a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (cns) disorders. in 2013 we launched oxtellar xr® and trokendi xr®, two novel neurology products for the treatment of epilepsy. we are also developing several product candidates in psychiatry to address unmet medical needs and opportunities in attention-deficit hyperactivity disorder (adhd) and its coexisting disorders, and depression. we are developing differentiated products by leveraging our proprietary and in-licensed technologies. we use such technologies to discover and develop novel uses for known drug compounds and to enhance their therapeutic benefits. our focus on known drug compounds with established mechanisms of action reduces the risks, costs, and time typically associated with pharmaceutical product development.
What does Supernus Pharmaceuticals Inc's logo look like?
Complete history of Stefan Schwabe stock trades at Supernus Pharmaceuticals Inc
Supernus Pharmaceuticals Inc executives and stock owners
Supernus Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Jack Khattar,
President, Chief Executive Officer, Secretary, Director -
Jack A. Khattar,
Founder, Pres, CEO, Sec. & Director -
Stefan Schwabe,
Executive Vice President - Research and Development, Chief Medical Officer -
Padmanabh Bhatt,
Senior Vice President - Intellectual Property, Chief Scientific Officer -
Tami Martin,
Senior Vice President - Regulatory Affairs -
Dr. Padmanabh P. Bhatt,
Chief Scientific Officer & Sr. VP of Intellectual Property -
Tami T. Martin,
Sr. VP of Regulatory Affairs -
Charles Newhall,
Independent Chairman of the Board -
Frederick Hudson,
Independent Director -
John Siebert,
Independent Director -
Georges Gemayel,
Independent Director -
Carrolee Barlow,
Independent Director -
Frank Mottola,
Senior Vice President, Quality, GMP Operations and Information Technology -
James Kelly,
Chief Financial Officer, Executive Vice President -
Jeff Bozick,
Sr. VP of Supply Chain -
Frank Mottola,
Sr. VP of Quality, GMP Operations & Information Technology -
Kevin T. Anderson,
Compliance Officer -
Timothy C. Dec,
Sr. VP & CFO -
Dr. Jonathan Rubin,
Sr. VP & Chief Medical Officer -
Dr. Bryan A. Roecklein,
VP of Corp. Devel. -
Taylor Raiford,
VP of Sales -
Dr. Todd Horich M.B.A., Ph.D.,
VP of Marketing -
William A. Nuerge,
Director -
M James Barrett,
Director -
Victor Vaughn,
Sr. VP of Sales -
Krishna Kittu Kolluri,
10% owner -
Advisors Llcisaly Samuel Do...,
-
Partners 11 Lp Nea,
10% owner -
Forest Baskett,
10% owner -
Michael Bigham,
Director -
Peter J Barris,
10% owner -
Enterprise Associates 11 Lp...,
10% owner -
Scott D Sandell,
10% owner -
Jones W. Bryan,
VP of Business Development -
Management Ltd Abingworth,
10% owner -
Advisors Llcorbimed Capital...,
-
Michael B Sheffery,
Director -
Gregory S Patrick,
Sr. VP Chief Financial Officer -
Jonathan Rubin,
SVP, Chief Medical Officer -
Timothy C Dec,
Senior Vice-President & CFO -
Bethany Sensenig,
Director